Newer generation antidepressants should carry a broader warning of an increased risk of suicidal thoughts and behaviors in not only children and adolescents, but also young adults, recommended a US Food and Drug Administration (FDA) advisory committee after considering new data from the agency. But in an unprecedented step, the panel also recommended that the warnings include information on the benefits of treating depression and the risk of suicide associated with untreated depression, based on emerging data that warnings about potential adverse effects of medications may lead to undertreatment and subsequent suicides.
Kuehn BM. FDA Panel Seeks to Balance Risks in Warnings for Antidepressants. JAMA. 2007;297(6):573-574. doi:10.1001/jama.297.6.573